NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Humane Genomics

Humane Genomics

Private
New York City, New YorkHealthcare & Life Scienceshttps://humanegenomics.com/

Last Round

Seed

Feb 12, 2025

Est. Valuation

$1.79M

Total Funding Raised

$125,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Humane Genomics is a biotechnology company that develops a synthetic virology platform to engineer oncolytic viral therapies for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

oncolytic viral therapysynthetic biologycancer therapeuticsoncolytic virusprecision medicinedrug discoveryclinical trialsviral vectorbiotechgene therapycodon optimizationbioinformaticstumor targetingonco-virotherapybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Humane Genomics Comparables

Compare Humane Genomics with similar companies based on industry and business-model similarity.

Humane Genomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Theolytics
85%
Lokon Pharma
81%
Akamis Bio
78%

Humane Genomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 12, 2025
AcceleratorAug 27, 2021
Pre SeedJan 14, 2020

Key People

Founding team and executive leadership

Chad Moles

Co-founder And Chief Science Officer

Founding Team

Peter Weijmarshausen

CEO Co-founder

Founding Team

Humane Genomics Investors

Notable investors and investment history

Humane Genomics investors
InvestorRounds
Union Square VenturesSeed
GaingelsSeed
2048 VenturesSeed, Pre Seed
Y CombinatorSeed, Accelerator
Scale Asia VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 51% MoM.

  • Apr 23, 2026

    Grew 50% QoQ, from 6 to 9 employees.

Humane Genomics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Humane Genomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Humane Genomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range9
Year Founded2016
Last FundingFeb 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.